Colorectal cancer (CRC) is the second leading cause of cancer-related death in Western populations. Indeed, around half of the population will develop at least one benign tumour during their lifetime ([@bib21]).

Several studies revealed a series of molecular events that are critical for the progression from colon adenoma to invasive carcinoma ([@bib10]; [@bib9]). One of the earliest events is the inactivating mutation in the *Adenomatous Polyposis Coli* (*APC*) tumour suppressor gene that leads to the activation of the Wnt signalling pathway, a key regulator of intestinal stemness. In fact, *Apc* loss is sufficient to induce multiple adenomas in the mouse intestine ([@bib35]; [@bib4]; [@bib6]). The *Apc*^Min/+^ (*multiple intestinal neoplasia*) mouse model carries a single *Apc* mutation that is sufficient to induce the development of hundreds of benign adenomas in the small intestine of the mice by 4 to 6 months of age. Besides *APC*, mutations in *KRAS*, *p53* and the transforming growth factor β (TGFβ) pathways are known to be crucial for CRC progression ([@bib10]; [@bib7]).

The current treatments for advanced CRC include surgery, and a combination of chemotherapies that are ineffective in a proportion of cases. Hence, it is of crucial importance to identify new therapeutic targets that can be exploited to improve CRC treatment and patient survival.

The nuclear factor-*κ*B (NF-*κ*B) is a key transcription factor that not only mediates innate and acquired immune responses but also regulates inflammation and carcinogenesis ([@bib19]; [@bib20]; [@bib34]). Activation of the pathway by different stimuli such as tumour necrosis factor-*α* (TNF*α*), bacterial and viral products or DNA damage induces the phosphorylation of the inhibitor of NF-*κ*B (I*κ*B) kinase (IKK) complex downstream of transforming growth factor *β*-activated kinase 1 (TAK1). This complex is composed by IKK*α*, IKK*β* and IKK*γ*/NF-*κ*B essential modulator (NEMO) ([@bib16]) that phosphorylates I*κ*B leading to its ubiquitination and subsequent degradation. Degradation of I*κ*B allows the nuclear translocation of the NF-*κ*B factor, mostly p65/p50 dimers, leading to the activation of the canonical pathway. The IKK*α* subunit also participates in the activation of the alternative NF-*κ*B pathway that is independent of IKK*β*, NEMO and TAK1 ([@bib37]). Specifically, factors inducing alternative NF-*κ*B lead to the stabilisation of the NF-*κ*B-inducing kinase (NIK) that in turn activates IKK*α* to phosphorylate p100. This cascade results in the proteolytic processing of p100 into p52 that will then translocate into the nucleus together with RelB to activate specific gene transcription.

Mostly related with its role in inflammation, several studies have demonstrated the association between NF-*κ*B, IKK*β* and cancer ([@bib22]). In parallel, other reports identified NF-*κ*B-independent functions that are carried out by elements of the pathway, thus contributing to specific tumourigenic capabilities. Some examples are found in squamous cell carcinoma (SCC), where IKK*α* induces the release of SUMO-I*κ*B*α* from the chromatin leading to HOX and IRX gene transcription ([@bib29]). Also in SCC, nuclear IKK*α* regulates the levels of the metastasis suppressor gene *Maspin* ([@bib36]), similar to that found in prostate cancer cells ([@bib24]). In CRC, nuclear IKK*α* regulates the transcription of Notch target genes by phosphorylating the silencing mediator for retinoid and thyroid receptors (SMRT) and the nuclear receptor corepressor (N-CoR) ([@bib11], [@bib12]). Moreover, the presence of nuclear active IKK*α* correlates with cancer progression, and we recently identified a novel IKK*α* isoform with a predicted molecular weight of 45 kDa (p45-IKK*α*) that lacks several regulatory regions at the C-terminal end of the kinase ([@bib27]). Active p45-IKK*α* localises in the nucleus of CRC cells and forms a complex with non-phosphorylated full-length IKK*α* and NEMO. Activation of this isoform involves the endosomal compartment and is induced by mutant BRAF^V600E^ through the kinase TAK1 ([@bib26]). Furthermore, a mouse model deficient in IKK*α* kinase activity displays reduced Wnt-driven intestinal tumour development associated with an enhanced recruitment of interferon-*γ* (IFN*γ*)-expressing M1-like myeloid cells ([@bib17]). These data demonstrate that IKK*α* is a key regulatory element of tumourigenesis that acts both in an NF-*κ*B-dependent and -independent manner. In the latter, IKK*α* might directly regulate essential factors that participate in the oncogenic process. However, to date, there are no conclusive data unveiling the contribution of intestinal epithelial IKK*α* neither in normal intestinal homeostasis nor in the oncogenic transformation of the intestinal stem and progenitor cells.

We have here generated mice with deletion of IKK*α* in the intestinal epithelial cells that were crossed with a model of intestinal tumourigenesis driven by *APC* mutation. We found that intestinal epithelial IKK*α* is essential for tumour formation while dispensable for normal tissue homeostasis, both in *in vivo* and 3D *in vitro* cultures. Moreover, by RNA sequencing of wild-type (WT) and IKK*α* knockout (KO) tumouroids, we uncovered the molecular basis of IKK*α* addiction in transformed cells.

Materials and methods
=====================

Animals
-------

For the generation of intestine-specific IKK*α* KO animals, the previously described *Ikkα*^FL^ mice ([@bib14]) were crossed with the Villin-Cre (from Jackson Laboratories, Bar Harbor, ME, USA) line, both in C57BL/6 background. *Apc*^Min/+^ mice (from Jackson Laboratories) were from C57BL/6J background. All mice were genotyped by PCR and animals were kept under pathogen-free conditions. All the animal work was conducted according to the guidelines from Generalitat de Catalunya.

Immunohistochemistry
--------------------

Formalin-fixed Swiss-roll intestinal samples were embedded in paraffin and sectioned at 4 *μ*m. After dewaxing and rehydration, antigen retrieval was achieved using standard methods depending on the antibodies. Endogenous peroxidase activity was quenched by incubating the sections for 20 min with 1.5% H~2~O~2~. Primary antibodies Ki67 (Novocastra, Newcastle, UK, MM1), cleaved caspase 3 (Cell Signaling, Danvers, MA, USA, 9661) and *β*-catenin (Sigma-Aldrich, St Louis, MO, USA, C2206) were diluted in PBS containing 0.05% BSA and incubated overnight at 4 °C. Samples were then incubated with specific horseradish peroxidase (HRP)-labelled polymer (EnVision+ System, DAKO, Glostrup, Denmark), and staining was developed using DAB+ Substrate (Chromogen System, DAKO).

Intestinal adenoma isolation and tumouroid culture in Matrigel
--------------------------------------------------------------

Intestinal crypts and adenomas used in the 3D cultures were isolated as previously described ([@bib32]). For organoid culture, we collected mouse small intestines, sliced them longitudinally and washed in cold PBS. Villi were removed by carefully scraping the surface, and the remaining tissue was cut into 3--5 mm sections. Samples were incubated twice in 2 m[M]{.smallcaps} EDTA for 30 min at 4 °C, filtered through a 100 *μ*m pore diameter nylon and centrifuged at 110 g to obtain the crypt-enriched fraction. For tumouroid cultures, adenomas were isolated manually and incubated in 8 m[M]{.smallcaps} EDTA for 20 min at 4 °C. The remaining pellet was treated for 20 min at 37 °C in agitation with 0.4 mg ml^−1^ dispase and subsequently with 1.25 mg ml^−1^ collagenase each. Cell suspension was centrifuged for 5 min at 1200 r.p.m. and resuspended in 140 n[M]{.smallcaps} ROCK inhibitor (Y-27632, Sigma) before filtration through 100, 70 and 40 *μ*m pore diameter nylon meshes, consecutively. After that, cells were centrifuged for 5 min at 1200 r.p.m. and seeded in Matrigel (Corning, Corning, NY, USA) drops.

Approximately 10^4^ cells were seeded in 50 *μ*l of Matrigel in 24-well plates. After polymerisation, 500 *μ*l of complete medium ((DMEM/F12, Biological Industries, Kibbutz Beit-Haemek, Israel) with penicillin (100 U ml^−1^) and streptomycin (100 *μ*g ml^−1^) (Biological Industries) supplemented with N2 and B27 (Invitrogen, Carlsbad, CA, USA) containing 140 n[M]{.smallcaps} ROCK inhibitor (Y27632, Sigma), 100 ng ml^−1^ Noggin (Peprotech, London, UK), 100 ng ml^−1^ R-spondin (R&D Systems Minneapolis, MN, USA), 50 ng ml^−1^ EGF (Sigma) and 20 ng ml^−1^ basic FGF (Peprotech)) was added and cultures maintained at 37 °C in 5% CO~2~. Tumouroid measurement was performed using the standard parameters in Fiji-ImageJ (<https://fiji.sc>).

Tumouroid immunostaining
------------------------

Tumouroids were seeded in Matrigel (Corning) onto a cover glass in a 24-well plate, and maintained in culture for 2 days. For whole-mount immunostaining, tumouroids were fixed with 4% paraformaldehyde for 20 min, permeabilised with 0.5% Triton X-100 (Pierce, Waltham, MA, USA) for 10 min and blocked in 2% BSA and 0.3% Triton X-100 for 1 h. Primary antibody (Ki67, Novocastra, MM1) was incubated overnight. After extensive washing, secondary antibody donkey-anti-mouse Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA) was incubated for 2 h at room temperature. Slides were mounted in ProLong Diamond Antifade with DAPI (Thermofisher, Waltham, MA, USA).

Western blot analysis
---------------------

Organoids and tumour spheroids were collected, centrifuged at 600 g for 5 min and lysed for 10 min at 4 °C in 100 *μ*l of RIPA buffer supplemented with complete protease inhibitor cocktail (Roche, Basel, Switzerland). Lysates were then sonicated for 10 min and analysed by western blot using standard SDS--polyacrylamide gel electrophoresis (SDS--PAGE) techniques. In brief, protein samples were boiled in Laemmli buffer, run in 8% polyacrylamide gels and transferred onto polyvinylidene difluoride membranes. The membranes were incubated overnight at 4 °C with the appropriate primary antibodies. After washing, membranes were incubated with specific secondary horseradish peroxidase-linked antibodies (DAKO) and visualised using the enhanced chemiluminescence reagent (Biological Industries).

Image analysis
--------------

The immunohistochemistry (IHC) of intestinal sections was visualised in an Olympus BX61 microscope (Olympus, Shinjuku, Tokyo, Japan), and images were taken using the cellSens Digital Imaging software (Olympus). Measurement of tumour spheroid length (diameter) was performed automatically with ImageJ Software (National Institutes of Health, Bethesda, MD, USA, <https://imagej.nih.gov/ij/>, 1997-2016) analysis. Quantification of IHC for Ki67 was done using Cell Profiler (Broad Institute, Cambridge, MA, USA). Immunofluorescence images of intestinal organoids and spheroids were taken in a Leica SP5 TCS upright microscope and the Leica Application Suite Advanced Fluorescence software (Wetzlar, Germany).

RNA-Seq experiment and analysis
-------------------------------

Total RNA from three biological replicates per condition was extracted using RNeasy Micro Kit (Qiagen, Hilden, Germany). The RNA concentration and integrity were determined using Agilent Bioanalyser (Agilent Technologies, Santa Clara, CA, USA). Libraries were prepared and sequenced at the CRG Genomics unit (Barcelona, Spain) using standard protocols on an Illumina HiSeq2500 (San Diego, CA, USA). Heatmaps were generated using R studio (<https://www.rstudio.com/>) and GSEA, and statistical analysis was performed with publicly available software from the Broad Institute (<http://www.broadinstitute.org/gsea/index.jsp>).

Results and discussion
======================

IKK*α* deletion in the intestinal epithelium reduces tumour formation and proliferation
---------------------------------------------------------------------------------------

The IKK/NF-*κ*B signalling pathway has emerged as a key regulator in multiple cancer types, including colon cancer ([@bib5]). However, NF-*κ*B also exerts multiple essential physiological functions affecting cell survival that makes its general inhibition extremely toxic ([@bib23]; [@bib15]; [@bib41]).

As IKK*α* is not required for this general NF-*κ*B function, and previous studies suggested its crucial role in intestinal tumourigenesis, we now studied the specific contribution of intestinal epithelial IKK*α* to neoplastic transformation. We used a mice strain carrying Cre recombinase under the control of *Villin* promoter (*Villin*-Cre). As *Villin* is specifically expressed in the epithelial cells of the small and large intestine ([@bib25]), crossing this strain with the one containing loxP site-flanked *Ikkα* ([@bib14]) resulted in tissue-specific deletion of the kinase. We then crossed intestinal-specific *Ikkα* KO mice with *Apc*^Min/+^ mice to induce intestinal cell transformation in an IKK*α*-deficient background ([Figure 1A](#fig1){ref-type="fig"}). All different genotypes were born at the expected Mendelian ratios and showed no evident growth defects during the first 3 months of age, indicating that intestinal epithelial IKK*α* was dispensable for tissue homeostasis (data not shown). Further analysis of 3-month-old animals carrying the *Apc*^Min/+^ allele demonstrated that IKK*α* deficiency imposed a significant decrease in the number of tumours arising in the small intestine when compared with the *Ikkα* WT littermates or mice carrying one copy of the *Ikkα* gene (*Ikkα*^+/−^) ([Figures 1B and C](#fig1){ref-type="fig"}). Next, we studied the possibility that reduced proliferation of transformed cells might contribute to the observed phenotype. By IHC analysis, we found that *Ikkα* WT adenomas showed a significantly higher percentage of proliferating Ki67-positive cells when compared with the *Ikkα* KO adenomas ([Figures 1D and E](#fig1){ref-type="fig"}). In contrast, we consistently failed to detect any histological difference or changes in the number of Ki67-positive cells in the nontransformed intestinal mucosa of *IKKα* WT, heterozygous or KO animals ([Figures 1F and G](#fig1){ref-type="fig"}). Because active *β*-catenin plays a pivotal role in *Apc*-mutant tumour initiation and maintenance ([@bib38]) and it was previously identified as a target of IKK*α* ([@bib1]), we aimed to determine whether nuclear *β*-catenin levels were reduced in the IKK*α* KO background. By IHC analysis we found that *Ikkα* KO tumours show a significant decrease in the levels of nuclear *β*-catenin as compared with the *Ikkα* control counterparts ([Figures 1H and I](#fig1){ref-type="fig"}).

We next explored the possibility that decreased tumour number in the *Apc*^Min/+^ *Ikkα* KO mice were associated to increased apoptosis of the transformed cells. To do so we checked the levels of cleaved caspase 3. By IHC analysis of *Ikkα* WT and KO *Apc*^Min/+^ intestines, we observed very few cleaved caspase 3-positive areas within the tumours of both *Ikkα* genotypes ([Figure 1J](#fig1){ref-type="fig"}). As a positive control, intestines of *γ*-irradiated mice showed consistent cleaved caspase 3 staining ([Figure 1K](#fig1){ref-type="fig"}).

These results indicate that intestinal epithelial IKK*α* is essential for tumour initiation and tumour cell proliferation, likely through regulation of *β*-catenin signalling, but it is dispensable for maintaining normal homeostasis and proliferation of the intestine, a situation that is clinically exploitable. Whether differences on *β*-catenin activation were due to direct phosphorylation by IKK*α* need to be further investigated.

IKK*α*^−/−^ tumouroids show a decrease in size and proliferation
----------------------------------------------------------------

The *in vivo* experiments described above provide strong evidence of the role of IKK*α* in tumour formation in the APC^Min/+^ mouse model. To further investigate the contribution of IKK*α* requirement in a pure intestinal epithelial tumour model, we used the *ex vivo* 3D culture system, in which single primary intestinal cells with tumour-initiating capability generate spheroidal structures ([@bib33], [@bib32]). We will here refer to these tumour spheroids as tumouroids. Consistent with our *in vivo* data, *Ikkα*^−/−^; *Apc*^Min/+^ adenoma cells generated tumouroids that were significantly smaller in size than *Ikkα* WT counterparts ([Figure 2A](#fig2){ref-type="fig"}). This growth-deficient phenotype was much more pronounced in the initial cultures and attenuated after serial passaging of the tumouroid cultures. The significance of this result was confirmed by a careful quantification of sphere diameter ([Figure 2B](#fig2){ref-type="fig"}). Similar to that observed in the normal intestine, 3D organoid cultures, which were derived from nontransformed intestinal epithelial stem cells, showed no differences in their growing capacity when comparing *Ikkα*^+/+^ and *Ikkα*^−/−^ genotypes ([Figure 2C](#fig2){ref-type="fig"}). Immunofluorescence analysis of Ki67 expression demonstrated that *Ikkα*^−/−^ tumouroids were almost depleted from proliferating cells compared with *Ikkα*^+/+^ structures ([Figures 2D and E](#fig2){ref-type="fig"}). These results identify epithelial IKK*α* as an important contributor to intestinal tumour initiation activity *ex vivo*.

IKK*α* governs tumouroid growth by regulating stem cell proliferation and cell cycle-related gene programmes
------------------------------------------------------------------------------------------------------------

We aimed to investigate the mechanisms underlying epithelial IKK*α* function in transformed cells by defining the transcriptional programmes that depend on IKK*α* in the *Apc*^Min/+^ tumouroids. We performed RNA-seq from *Apc*^Min/+^ *Ikkα* WT or IKK*α* KO tumouroid cells. Data are accessible at the NCBI GEO database ([@bib8]), accession GSE101415. Unsupervised cluster analysis demonstrated a clear co-segregation of WT and KO RNA samples ([Figure 3A](#fig3){ref-type="fig"}). Importantly, the transcriptional profile of *Ikkα* KO tumouroids showed a significant decrease in the levels of a previously defined intestinal stem cell (ISC) signature ([@bib30]) ([Figure 3B](#fig3){ref-type="fig"}), including genes essential for maintaining ISC function such as *Notch1* ([@bib31]; [@bib13]), *Cdca7* ([@bib18]), *Lgr5* ([@bib2]), *Ephb2* ([@bib3]; [@bib28]), *Ascl2* ([@bib39]) or *Lrig1* ([@bib40]), among others. We further confirmed these results by qRT--PCR of several of these genes in a different set of tumouroids from both genotypes ([Figure 3C](#fig3){ref-type="fig"}). By Gene Set Enrichment Analysis (GSEA) we identified several pathways that were miss-regulated in the IKK*α*-deficient adenoma cells compared with the WT. This applies to the apoptosis pathway that was significantly enriched in the absence of IKK*α* ([Figures 3D and F](#fig3){ref-type="fig"}), involving genes such as *RIPK1*, *TRADD*, *FASLG*, *FAS* and *CASP8* among others. In contrast, IKK*α*-deficient adenomas showed a decrease in cell cycle-related genes ([Figure 3D](#fig3){ref-type="fig"}). IKK*α* deficiency also led to a decrease in the pro-tumourigenic MYC signature, whereas it did not correlate with a general reduction in the canonical NF-*κ*B signature ([Figures 3E and F](#fig3){ref-type="fig"}), further suggesting that IKK*α* function in the intestinal adenoma stem cells is mainly NF-*κ*B independent. These results are in agreement with our previous data indicating that IKK*α* regulates cell survival and proliferation in human CRC cells ([@bib11]; [@bib27], [@bib26]).

Collectively, our results demonstrate that intestinal epithelial IKK*α* exerts a cell-autonomous function in the intestinal adenoma stem cells affecting proliferation and stemness. Importantly, our data support the concept that IKK*α* is a plausible target for the development of new anticancer therapies from which CRC patients could benefit. Further investigation on the upstream and downstream effectors of cancer-associated IKK*α* activity will provide valuable information for the design of better and more selective therapies against human CRC. In fact, identification of the apoptotic pathway as a target of IKK*α* supports the notion that its inhibition could sensitise tumour cells to compounds that induce cell death such as chemotherapeutic agents.
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![**The *IKKα* deletion in the intestinal epithelium reduces adenoma formation and proliferation.** (**A**) Schematic representation of the strategy used to generate the compound mice used in our study. (**B**) Representative images of H&E staining of *Apc*^Min/+^;*Ikkα*^+/+^ and *Apc*^Min/+^;*Ikkα*^−/−^ intestinal Swiss rolls. Dashed lines delimited two different tumours present in the *Apc*^Min/+^;*Ikkα*^+/+^ image. (**C**) Quantification of tumour number in the *Apc*^Min/+^;*IKKα*^+/+^ and *APC*^Min/+^;*IKKα*^−/−^ intestinal Swiss rolls. (**D**) Representative images of Ki67 immunohistochemistry (IHC) in A*pc*^Min/+^; *Ikkα*^+/+^ and *Ikkα*^−/−^ adenomas. (**E**) Quantification of Ki67-positive cells shown in (**D**). (**F**) Immunohistochemistry of Ki67 in *Ikkα*^+/+^ and I*kkα*^−/−^ intestines and (**G**) quantification of the number of Ki67-positive cells per hemi-crypt. Graphs represent the average number of tumours (**C**) or percentage of cells (**E** and **G**) per Swiss roll from animals of each genotype. (**H** and **I**) The IHC analysis of *β*-catenin (**H**) and quantification of percentage of tumour cells of each genotype showing nuclear *β*-catenin staining (**I**). (**J** and **K**) The IHC of cleaved caspase 3 in tumours of the indicated genotypes (**J**) or obtained from mice irradiated 3 h before processing the samples (**K**). Representative images for (**H**, **J** and **K**) are shown. For statistical analysis, ordinary one-way ANOVA or unpaired *t*-test was used and the *P*-values are indicated as \*\*\**P*\<0.001 and \*\*\*\**P*\<0.0001.](bjc2017459f1){#fig1}

![***Ikkα*^−/−^ tumouroids show a decrease in size and proliferation.** (**A**) Representative images of growing tumouroids from the indicated genotypes. Western blot analysis of IKK*α* is shown in the right panel. P=passage. (**B**) Quantification of tumouroid length from three independent experiments performed. (**C**) Representative images of organoid cultures from nontransformed *Ikkα*^+/+^ and *Ikkα*^−/−^ intestinal stem cells and western blot analysis to demonstrate the efficiency of *Ikkα* deletion. Western blot showing the levels of *Ikkα* in a representative culture from the indicated genotype (right panel). (**D**) Immunofluorescence (IF) staining of Ki67 in the *Apc*^Min/+^ *Ikkα*^+/+^ and *Ikkα*^−/−^ tumouroids from passage 6 grown in Matrigel (Corning). (**E**) Quantification of the percentage of Ki67-positive cells from three independent experiments that was performed as in (**D**). The graph shows the average percentage and s.d. of the mean. Magnification of images is indicated. For statistical analysis we used ordinary one-way ANOVA or unpaired *t*-test. *P-*values are indicated as \**P*\<0.05, \*\*\**P*\<0.001 and \*\*\*\**P*\<0.0001.](bjc2017459f2){#fig2}

![***Ikkα*^−/−^ tumouroids show altered regulation of intestinal stem cell genes.** (**A**) Unsupervised hierarchical clustering analysis based on Euclidean distances of logged normalised counts between samples from three independent samples per genotype analysed. (**B**) The RNA-seq heatmap showing differential expression of genes involved in intestinal stemness with scaled (*z*-score) columns. (**C**) The q-PCR analysis of the indicated genes in *Ikkα*^+/+^ (WT) and *Ikkα*^−/−^ (KO) tumouroids. The graphs represent the average value and s.d. from two independent tumouroids of each genotype analysed in triplicate. (**D**) The GSEA plots of genes differentially expressed in *Ikkα* WT and KO from the apoptosis and cell cycle checkpoint-related gene sets. (**E**) The GSEA plots of differentially expressed genes from MYC- and NF-*κ*B-related gene sets. The pathways shown were particularly selected from significantly enriched ones to better explain the phenotypes observed. (**F**) Table showing all signatures from Hallmark gene sets that were significantly enriched (*P*\<0.01 and FDR \<0.025) in *Ikkα*^+/+^ or *Ikkα*^−/−^ tumouroids. Of note that cell cycle checkpoint-related gene set was identified from Reactome gene sets. *P*-value and false discovery rate (FDR) are shown. For statistical analysis we used ordinary one-way ANOVA or unpaired t-test. DN=down; KO=knock out; NES=normalised enrichment score; WT=wild-type. P-values are indicated as \*\**P*\<0.01 and \*\*\**P*\<0.001.](bjc2017459f3){#fig3}
